In this review, we outline recent advancements in small molecule drug design from a
structural perspective. We compare protein structure prediction methods and explore the …

Hypogammaglobulinemia (HGG) is a frequent finding in patients with hematological
malignancies, and is commonly described in chronic lymphocytic leukemia (CLL) before or …

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic B
lymphocytes with high levels of Wnt5a in the plasma. Currently, the cell source of Wnt5a …

BTK inhibitors, Bcl-2 inhibitors, and other targeted therapies have significantly improved the
outcomes of patients with chronic lymphocytic leukemia (CLL). With increased survivorship …

Targeting the metabolic dependencies of acute myeloid leukemia (AML) cells is a promising
therapeutical strategy. In particular, the cysteine and methionine metabolism pathway (C/M) …

Simple Summary Cancer develops when the balance between cell death and cell division in
tissues is dysregulated. A key focus of cancer drug discovery is identifying therapeutic …

Simple Summary The recent growing interest in intermittent fasting (IF) is attributed to its
preclinical benefits in various aspects of cancer management. Novel agents, namely …

Apoptosis plays a significant role in both carcinogenesis and cancer treatment. Apoptotic
dysfunction may allow cancer cells to survive. Overexpression of anti-apoptotic B cell …

Venetoclax is a Bcl-2 homology domain 3 (BH3) mimetic currently approved for the
treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) that has …

L'allogreffe de cellules hématopoïétiques (allo-CH) est un traitement curatif de nombreuses
hémopathies malignes et non malignes. La prévention de la rechute hématologique, des …